Petmed Express (PETS)

NASDAQ:PETS

PETS

Petmed Express

RESEARCH TOOLSreports

Want to see PETS full AI Analyst Report?

Petmed Express (PETS) Earnings Dates, Call Summary & Reports

Q: When does Petmed Express (PETS) report earnings?

Petmed Express (PETS) is schdueled to report earning on Jul 27, 2026, Before Open (Confirmed).

Q: What is Petmed Express (PETS) earnings time?

Petmed Express (PETS) earnings time is at Jul 27, 2026, Before Open (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is PETS EPS forecast?

PETS EPS forecast for the fiscal quarter 2027 (Q1) is 0.12.

876 Followers

Earnings Data

Report Date

Jul 27, 2026

Before Open (Confirmed)

Period Ending

2027 (Q1)

Consensus EPS Forecast

0.12

Last Year’s EPS

-0.07

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2026

Earnings Call Date:Jun 02, 2026|

% Change Since:

Earnings Call Sentiment|Negative

The call highlights meaningful operational, governance and technology progress — including remediation of material weaknesses, cost-savings actions (~$6.1M annualized), Q4 sequential sales improvement, expanded tech infrastructure, and a clean balance sheet with $21.4M cash and no debt. However, these positives were offset by significant financial deterioration: a 21.1% decline in FY sales, a substantial FY net loss of $57.3M driven largely by a $26.7M goodwill impairment and other nonrecurring charges, and negative adjusted EBITDA of $15.4M. Management emphasized stabilization and early signs of improvement in the second half, but the magnitude of the year-over-year deterioration in top-line and profitability represents a material near-term challenge.

Company Guidance

The company provided directional guidance rather than specific FY27 targets, saying it will build on fiscal 2026 operational, financial and cultural fixes to drive sustainable long‑term results through operational excellence, improved customer retention and B2B/white‑label expansion (including a Master Services Agreement with Rural King). Management cited metrics showing early momentum—FY26 net sales $179.0M (down 21.1% from $227.0M), Q4 net sales $42.8M (down 15.6% year‑over‑year, or down 17.8% adjusted for the New York sales tax settlement) with a sequential Q4 sales increase (the first Q4 sequential increase since FY24); Q4 gross profit $13.9M (32.6%, up 270 bps), Q4 net loss $4.1M or $0.19 per diluted share (vs. $11.6M/$0.56 prior year), FY net loss $57.3M or $2.74 per diluted share, FY adjusted EBITDA negative $15.4M (vs. +$0.7M prior year) and Q4 adjusted EBITDA loss $2.8M. They highlighted balance‑sheet and cost actions—$21.4M cash, no debt, remediation of 3 material weaknesses, implementation of a new ERP, fraud and call‑center systems, ~$6.1M of annualized savings from exiting vendors, a $2.8M benefit from settling the NY tax liability—and cautioned FY26 included one‑time items (a $26.7M goodwill impairment, $2.1M inventory write‑down and $4.5M legal/professional/severance), so near‑term guidance is focused on translating these improvements into revenue stabilization and EBITDA recovery rather than issuing specific numeric guidance today.

Sequential Q4 Improvement and Lower Q4 Net Loss

Q4 net sales of $42.8M (down 15.6% YoY) showed a sequential quarterly increase from Q3 — the first Q4 sequential increase since FY2024. Q4 net loss improved to $4.1M ($0.19 per diluted share) vs. $11.6M ($0.56) in the prior-year quarter.

Gross Margin Expansion in Q4

Q4 gross profit of $13.9M with gross margin of 32.6% vs. 29.9% prior year, a 270 basis-point improvement primarily driven by the settlement of the New York sales tax liability.

Full-Year Cost Savings and Lowered Cost Structure

Exited underperforming vendor relationships expected to yield approximately $6.1M in annualized savings and G&A for Q4 down 8.6% YoY ($11.4M vs $12.5M) reflecting cost optimization efforts.

Remediation of Material Weaknesses and Governance Actions

Fully remediated three previously disclosed material weaknesses (tone at the top, complex accounting issues, and income taxes) and completed external auditor change to Baker Tilly U.S. LLP; filings brought current (10-K and subsequent quarterly filings).

Technology and Operational Modernization

Implemented new ERP, new fraud prevention system, and new call center technology, modernizing the tech stack and reducing operational risk; these are positioned to support improved customer experience and retention.

Operational and Customer Improvements

Second-half 'green shoots' observed: improvements in prescription medication sales, prescription and nonprescription food sales, autoship sign-ups, and improved customer-facing operational metrics and employee satisfaction.

Strong Balance Sheet Liquidity and No Debt

As of March 31, 2026, cash and cash equivalents of $21.4M and zero debt, providing liquidity to support operations and transformation efforts.

Strategic B2B Growth Opportunities

Pursuing B2B expansion including white-label pharmacy fulfillment and a Master Services Agreement with Rural King to leverage pharmacy infrastructure and reach new customers.

Petmed Express (PETS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PETS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 27, 2026	2027 (Q1)	0.12 / -	-0.07	―	―	―
Jun 02, 2026	2026 (Q4)	-0.18 / -0.19	-0.49	61.22% (+0.30)	―
Jan 27, 2026	2026 (Q3)	-0.06 / -0.50	-0.03	-1566.67% (-0.47)	―	―
Nov 03, 2025	2026 (Q2)	0.04 / 0.04	0.11	-63.64% (-0.07)	―	―
Jul 28, 2025	2026 (Q1)	- / -	0.18	―	―	―
Jul 01, 2025	2025 (Q4)	-0.02 / -0.07	0.18	-138.89% (-0.25)	―	―
Feb 10, 2025	2025 (Q3)	<0.01 / -0.03	-0.1	70.00% (+0.07)	―
Nov 06, 2024	2025 (Q2)	-0.06 / 0.11	0	―	―
Aug 06, 2024	2025 (Q1)	-0.09 / 0.18	-0.04	550.00% (+0.22)	―
Jun 11, 2024	2024 (Q4)	-0.07 / -0.25	-0.25	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PETS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 02, 2026	$2.13	$1.78	-16.43%
Jan 27, 2026	$3.27	$3.24	-0.92%
Nov 03, 2025	$2.57	$2.44	-5.06%
Jul 28, 2025	$3.77	$3.55	-5.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.